Search - tctmd.com

Displaying 461 - 480 of 8219

Sort: Relevancy | Date

Presentation TCT 2016

Assessment and Critical Appraisal of Ongoing RDN Studies: Will the Results Accurately Reflect RDN Effectiveness?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Justin E. Davies

October 30, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, David E. Kandzari

October 30, 2016

Presentation TCT 2016

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

TCT 500: Global Right Ventricular Longitudinal Peak Systolic Strain Predicts clinical Outcome After Pulmonary Artery Denervation for Patients with Pulmonary Arterial Hypertension

Presenter: Irene M. Lang, Ehtisham Mahmud

October 30, 2016

Presentation TCT 2016

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

Presenter: Eugene H. Blackstone, Robert W. Yeh, Kirk N. Garratt

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Kona WAVE IV Trial

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Roland E Schmieder

October 30, 2016

Presentation TCT 2016

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Presenter: Mayank Yadav

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Recor RADIANCE HTN Study

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Laura Mauri

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

Presentation TCT 2016

Value and Hazards of Subgroup Analysis: the SYNTAX to EXCEL Case Study

Presenter: Peter Juni, E. Magnus Ohman, Ori Ben-Yehuda

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: St. Jude's EnligHTN Program

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, William B. White

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Stephan Windecker

October 30, 2016

Presentation TCT 2016

Clinical Trial Interpretation: Relative vs Absolute Differences

Presenter: Peter Juni, E. Magnus Ohman, John A. Bittl

October 30, 2016

Presentation TCT 2016

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Matthew J. Price

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Medtronic GLOBAL SYMPLICITY SPYRAL HTN Trial Program

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, David E. Kandzari

October 30, 2016

Presentation TCT 2016

The Last Word on DES in Diabetics: Two-Year TUXEDO Outcomes

Presenter: Dean J. Kereiakes, Pieter C. Smits, Upendra Kaul

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Advertisement

Assessment and Critical Appraisal of Ongoing RDN Studies: Will the Results Accurately Reflect RDN Effectiveness?

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

TCT 500: Global Right Ventricular Longitudinal Peak Systolic Strain Predicts clinical Outcome After Pulmonary Artery Denervation for Patients with Pulmonary Arterial Hypertension

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

Device Overview and Ongoing Study Design: Kona WAVE IV Trial

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Device Overview and Ongoing Study Design: Recor RADIANCE HTN Study

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Value and Hazards of Subgroup Analysis: the SYNTAX to EXCEL Case Study

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Device Overview and Ongoing Study Design: St. Jude's EnligHTN Program

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Clinical Trial Interpretation: Relative vs Absolute Differences

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Device Overview and Ongoing Study Design: Medtronic GLOBAL SYMPLICITY SPYRAL HTN Trial Program

The Last Word on DES in Diabetics: Two-Year TUXEDO Outcomes

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content